A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies-Reference-Cited by-同舟云学术

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Published:2009-11-10 Issue:22 Volume:15 Page:7085-7091
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

O'Connor Owen A.,Stewart A. Keith,Vallone Marcy,Molineaux Christopher J.,Kunkel Lori A.,Gerecitano John F.,Orlowski Robert Z.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primed for Interactions: Investigating the Primed Substrate Channel of the Proteasome for Improved Molecular Engagement;Molecules;2024-07-17

2. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07

3. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries;International Journal of Molecular Sciences;2024-06-11

4. Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2;eLife;2024-04-15

5. The nociceptive activity of peripheral sensory neurons is modulated by the neuronal membrane proteasome;Cell Reports;2024-04